152922-71-9

Basic information

• Product Name: 1-(Hydroxymethyl)cyclopropaneacetonitrile
• Synonyms: [1-(HYDROXYMETHYL)CYCLOPROPYL]ACETONITRILE;2-[1-(HYDROXYMETHYL)-CYCLOPROPYL]-ACETONITRILE;Montelukast Intermediates;1-Hydroxymethyl Cyclopropyl Acetonitrile (Montelukast Intermediates);[1-(Hydroxymethyl)cyclopropyl]acetonitrile 97%;1-(Hydroxymethyl)cyclopropaneacetonitrile;1,1-cyclopropane dimethanol cylic sufite;1-(Hydroxymethyl)cycolpropane acetonitrile
• CAS NO: 152922-71-9
• Molecular Formula: C₆H₉NO
• Molecular Weight: 111.14
• EINECS: 1312995-182-4
• Product Categories: Ring Systems
• Mol File: 152922-71-9.mol

Chemical Properties

• Boiling Point: 245.1 °C at 760mmHg
• Flash Point: 102.1 °C
• Appearance: white or almost white power
• Density: 1.098 g/cm³
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.489
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Methanol (Slightly)
• PKA: 15.10±0.10(Predicted)
• CAS DataBase Reference: 1-(Hydroxymethyl)cyclopropaneacetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Hydroxymethyl)cyclopropaneacetonitrile(152922-71-9)
• EPA Substance Registry System: 1-(Hydroxymethyl)cyclopropaneacetonitrile(152922-71-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• Hazardous Substances Data: 152922-71-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(Hydroxymethyl)cyclopropaneacetonitrile is used as a reactant for the preparation of benzothiazoles and thiazoles substituted benzyl alcohols. These compounds are potent LTD4 (leukotriene D4) antagonists, which play a significant role in the treatment of asthma and other inflammatory diseases. The compound's unique structure allows for the development of new drugs with improved efficacy and reduced side effects.

InChI:InChI=1/C6H9NO/c7-4-3-6(5-8)1-2-6/h8H,1-3,5H2

Upstream product

• 39590-81-3 [1-(hydroxymethyl)cyclopropyl]methanol 
• 143-33-9 sodium cyanide 
• 3580-97-0 3-bromo-2,2-bis(bromomethyl)propyl acetate 
• 1522-92-5 2,2-bis(bromomethyl)-3-bromo-propan-1-ol 
• 115-77-5 Pentaerythritol 
• 142148-13-8 1-hydroxymethylcyclopropylacetic acid methyl ester 
• 855473-50-6 1-bromomethylcyclopropyl acetic acid methyl ester 
• 89729-09-9 5,7-dioxa-6-thia-spiro[2.5]octane 6-oxide 
• 90087-10-8 [1-(cyanomethyl) cyclopropyl]methyl acetate 
• 4773-13-1 diisopropyl sulfite 
• 869066-76-2 1-(p-methoxybenzoyloxymethyl)cyclopropane-1-acetonitrile 
• 4437-68-7 5,7-dioxa-spiro[2.5]octan-6-one 
• 13435-20-6 tetraethylammoniumcyanide 
• 773837-37-9 sodium cyanide 

Downstream Products

• 338392-48-6 2-(1-(bromomethyl)cyclopropyl)acetonitrile 
• 162515-68-6 1-(sulfanylmethyl)cyclopropaneacetic acid 
• 1087347-36-1 tert-butyl (3R,4S)-3-{[[3-({1-[2-(benzyloxy)-2-oxoethyl]cyclopropyl}methoxy)-5-(3-methoxypropyl)benzyl](cyclopropyl)amino]carbonyl}-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 1087347-37-2 tert-butyl (3R,4S)-3-{[(cyclopropyl)(3-(3-methoxypropyl)-5-{[1-(2H-tetrazol-5-ylmethyl)cyclopropyl]methoxy}benzyl)amino]carbonyl}-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 1087347-35-0 (1-{[3-{[[((3R,4S)-1-(tert-butoxycarbonyl)-4-{4-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidin-3-yl)carbonyl](cyclopropyl)amino]methyl}-5-(3-methoxypropyl)phenoxy]methyl}cyclopropyl)acetic acid 
• 1087347-34-9 tert-butyl (3R,4S)-3-({(cyclopropyl)[3-{[1-(2-methoxy-2-oxoethyl)cyclopropyl]methoxy}-5-(3-methoxypropyl)benzyl]amino}carbonyl)-4-{4-[2-(2.,6-dichloro-4-methylphenoxy)ethoxy]phenyl}piperidine-1-carboxylate 
• 1026787-28-9 tert-butyl (3R,4S)-3-(((3-((1-(cyanomethyl)cyclopropyl)methoxy)-5-(3-methoxypropyl)-benzyl)(cyclopropyl)amino)carbonyl)-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)-piperidine-1-carboxylate 
• 869066-83-1 2‐[1‐(hydroxymethyl)cyclopropyl]acetic acid 
• 142148-13-8 1-hydroxymethylcyclopropylacetic acid methyl ester 

Relevant articles and documents

Preparation method of 1-hydroxymethylcyclopropyl acetonitrile

The present invention relates to a method for preparing 1-hydroxymethylcyclopropyl acetonitrile, which belongs to the field of pharmaceutical intermediate synthesis technology. The present invention takes pentaerythritol as raw material, after bromination reaction to give tribromo neoamyl alcohol, and then by acetylation reaction to give 3-bromo-2,2-bis (bromomethyl) propyl acetate, the starting material is selected pentaerythritol, the reaction temperature is reduced from 90 ° C to 50 ° C, the reaction time is shortened from about 35 hours to about 10 hours, shortening the reaction time, reducing the reaction temperature, greatly reducing the production cost; the use of bromine-containing materials in the reaction process, to achieve the recovery of bromine elements, greatly reducing the output of waste, At the same time, it also solves the problem that cyclopropyl dimethylol contains two hydroxyl groups, only one hydroxyl group needs to be protected; further, the present invention uses a cyanide solution instead of a cyanide solid, reducing the risk of direct contact between the operator and the cyanide-containing material. The raw materials used in the present invention are simple and readily available, the process flow is simple, suitable for industrial large-scale production.

Montelukast side chain intermediate and preparing method thereof

The invention belongs to the field of medical chemistry, and particularly relates to a montelukast side chain intermediate and a preparing method thereof. A provided intermediate compound is 6-halogenated methyl-5,7-dioxaspiro[2,5] octane, wherein 1,1-cyclopropyl dimethyl carbinol serving as a starting material and 2-halogeno-1,1-dimethoxyethane are subjected to a transacetalation reaction under solid acid catalysis to obtain 6-halogenated methyl-5,7-dioxaspiro[2,5] octane, the intermediate is treated with organic alkali and then hydrolyzed with a water solution containing acetic acid to obtain monoacetylated protected diol. The problems that monoacetylated protected diol is poor in selectivity, and diol loss is serious are solved, the availability of the raw materials is improved, and the montelukast side chain intermediate can be synthesized economically and conveniently.

SPIROPYRROLIDINES AS MDM2 INHIBITORS

Described are spiropyrrolidines (I) useful as inhibitors of MDM2/p53 interactions and provides useful agents for the treatment of diseases like cancer and retinal macular degeneration diseases. The invented compounds herein have the general Further described are pharmaceutical compositions that comprise one or more compounds of the invention, a pharmaceutically acceptable salt or pro-drug and/or a pharmaceutically acceptable carrier or excipient.

PREPARATION OF MONTELUKAST AND ITS SALTS

There is provided a process for the preparation of montelukast of the Formula (I).

Process for preparation of [1-(mercaptomethyl)cyclopropyl]acetic acid and related derivatives

The present invention provides a novel process for preparing [1-(mercaptomethyl)cyclopropyl]acetic acid with high purity and related derivatives.

Process for making montelukast and intermediates therefor

A process for making montelukast, a pharmaceutically useful compound of the following formula and salts thereof: using a compound of formula (20) is provided.

ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO

The present invention provides Aryl Sulfonamide Compounds having the formula: (I); and prodrugs or pharmaceutically acceptable salts or prodrugs thereof. The Aryl Sulfonamide Compounds are useful for treating diabetes, obesity, and other diseases and disorders.

Preparation of cyclic sulfites by transesterification of diols and diisopropyl sulfite

Cyclic sulfites of 1,2-, 1,3- and 1,4-diols can be prepared in high yield by acid or base catalyzed transesterification with diisopropyl sulfite.

Process for the preparation of leukotriene anatgonists

The present invention relates to a process for the preparation of a compound of formula (I) or a sodium salt thereof STR1 wherein HET is 7-chloroquinolin-2-yl or 6,7-difluoroquinolin-2-yl, which comprises: reacting the dilithium dianion of 1-(mercaptomethyl)cyclopropaneacetic acid with a compound of formula (II) STR2 wherein HET is as defined above and L is arylsulfonyl or alkylsulfonyl. The invention further provides the dicyclohexylamine salt of a compound of formula (I).

Process for the preparation of 1-(thiomethyl)-cyclopropaneacetic acid

The present invention provides a novel process for the preparation of 1,1-cyclopropanedimethanol cyclic sulfite which comprises: (a) contacting 1,1-cyclopropanedimethanol with dialkylsulfite in the presence of a base; and (b) removing from the reaction mixture the alcohol reaction by-product. This process is incorporated in the additional novel processes for preparing 1-(hydroxymethyl)cyclopropaneacetonitrile and 1-(thiomethyl)cyclopropaneacetic acid.